Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

184.25 -1.02 (-0.55%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	745,829
Open	185.55
Bid (Size)	180.56 (100)
Ask (Size)	184.80 (100)
Prev. Close	185.27
Today's Range	180.56 - 188.00
52wk Range	86.99 - 191.50
Shares Outstanding	47,190,970
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23

January 27, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

The Great Rotation: Russell 2000’s Historic 15-Day Streak Marks a Seismic Shift in Market Leadership

January 26, 2026

In a move that has rewritten the record books of Wall Street, the small-cap-heavy Russell 2000 index recently concluded a historic 15-session winning streak of daily outperformance against the S&P 500....

Via MarketMinute

Performance

YTD	+3.1%	+3.1%
1 Month	+0.9%	+0.9%
3 Month	+36.5%	+36.5%
6 Month	+78.8%	+78.8%
1 Year	+69.3%	+69.3%

More News

AXSM Stock Rises After Analyst Hikes Price Target On Auvelity Drug Optimism ↗

January 16, 2026

Via Stocktwits

AXSOME THERAPEUTICS INC (NASDAQ:AXSM) Fits the Minervini Growth Momentum Strategy ↗

January 12, 2026

Via Chartmill

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia

January 15, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue

January 12, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out ↗

January 08, 2026

Via MarketBeat

2 Healthcare Stocks to Buy for 2026 and Beyond ↗

January 08, 2026

Via The Motley Fool

Regencell Bioscience (RGC) Stumbles into 2026: 8% Year-End Slide Sparks Technical Caution

January 01, 2026

Via MarketMinute

Here are the top movers in Wednesday's session. ↗

December 31, 2025

Via Chartmill

Why Axsome Therapeutics Stock Rocketed Higher to End 2025 ↗

December 31, 2025

Via The Motley Fool

The market is filled with gapping stocks in Wednesday's session. ↗

December 31, 2025

Via Chartmill

Axsome Advances Toward FDA Filing For Drug To Treat Narcolepsy ↗

December 31, 2025

Via Stocktwits

Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation

December 31, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission

December 31, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

2 Under-the-Radar Stocks to Buy Heading Into 2026 ↗

December 01, 2025

Via The Motley Fool

Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth

December 11, 2025

Via MarketMinute

Axsome (AXSM) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Via The Motley Fool

Axsome Therapeutics to Participate in Upcoming Investor Conferences

November 20, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Pomerantz LLP and The Rosen Law Firm, P.A. Announce Proposed Class Action Settlement on Behalf of Purchasers of Axsome Therapeutics, Inc. Common Stock - AXSM

November 10, 2025

From Pomerantz LLP

Via GlobeNewswire

2 Monster Stocks in the Making ↗

November 10, 2025

Via The Motley Fool

Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy

November 06, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Inc (NASDAQ:AXSM) Q3 2025 Earnings: Revenue Beat Overshadowed by Wider-Than-Expected Loss ↗

November 03, 2025

Via Chartmill

Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

November 03, 2025

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Axsome Therapeutics, Inc. - Common Stock publicly traded?

Yes, Axsome Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Axsome Therapeutics, Inc. - Common Stock trade on?

Axsome Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Axsome Therapeutics, Inc. - Common Stock?

The ticker symbol for Axsome Therapeutics, Inc. - Common Stock is AXSM on the Nasdaq Stock Market

What is the current price of Axsome Therapeutics, Inc. - Common Stock?

The current price of Axsome Therapeutics, Inc. - Common Stock is 184.25

When was Axsome Therapeutics, Inc. - Common Stock last traded?

The last trade of Axsome Therapeutics, Inc. - Common Stock was at 01/30/26 04:00 PM ET

What is the market capitalization of Axsome Therapeutics, Inc. - Common Stock?

The market capitalization of Axsome Therapeutics, Inc. - Common Stock is 8.69B

How many shares of Axsome Therapeutics, Inc. - Common Stock are outstanding?

Axsome Therapeutics, Inc. - Common Stock has 9B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.